Peripheral Artery Disease (PAD)

This channel includes news, interventions, and new technology innovations for peripheral artery diease, PAD and critical limb ischemia. 

New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019

June 20, 2019 – VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between...

Philips Shares Three-Year Results for Stellarex .035 Drug-Coated Balloon
News | Drug-Eluting Balloons | May 29, 2019

May 29, 2019 — Philips announced the three-year results from the ILLUMENATE Pivotal trial and the ILLUMENATE...

Intact Vascular Inc. received U.S. Food and Drug Administration (FDA) market clearance for the Tack Endovascular System. This is a purpose-built dissection repair device implanted post-angioplasty in patients with peripheral arterial disease (PAD).
Technology | Peripheral Artery Disease (PAD) | April 15, 2019

April 15, 2019 – Intact Vascular Inc. received U.S. Food and Drug Administration (FDA) market clearance for the Tack...

DABRA Excimer Laser System Demonstrates Success in Treating PAD
News | Cath Lab | February 27, 2019

February 27, 2019 — Ra Medical Systems Inc. announced a 98 percent success rate in the results from a 52-patient...

The Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Scientific Sessions in Las Vegas, May 19-22, with feature a peripheral vascular track with interactive sessions. Henry Ford Hospital CTO case.
Feature | SCAI | February 25, 2019 | Subhash Banerjee, M.D., FSCAI, Abu-Fadel Mazen, M.D., FSCAI and Rajesh Swaminathan, M.D., FSCAI
Two devices where safety is being called into question based on clinical data that is being questioned. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in a study questioning long-term safety of paclitaxel. The Abiomed Impella RP had higher than expected mortality in its post-approval study, possibly due to poor patient selection and implanting the device too late to aid the patient.

Two device technologies raised concerns in the industry based on recently released clinical data. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in a study questioning long-term safety of paclitaxel. The Abiomed Impella RP had higher than expected mortality in its post-approval study, possibly due to poor patient selection and implanting the device too late to aid the patient.

Blog | Cath Lab | February 20, 2019

Clinical study data makes the world go around in cardiology and is the basis of setting guidelines in evidence-based...

JETi Thrombectomy System Safe and Effective for Deep Vein Thrombosis
News | Thrombectomy Devices | February 12, 2019

February 12, 2019 — A study presented at the 2018 annual meeting of the Cardiovascular and Interventional Radiology...

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor

In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...

Philips Releases Three-Year Data on Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons | January 28, 2019

January 28, 2019 — Philips announced the latest pooled analysis of patient-level data of over 2,300 patients treated...

The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

Feature | Peripheral Artery Disease (PAD) | January 25, 2019 | Dave Fornell, Editor

The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since...

Lumee Oxygen Platform Measures Treatment Response in Critical Limb Ischemia
News | Peripheral Artery Disease (PAD) | January 25, 2019

January 25, 2019 — Profusa announced promising...

FDA Issues Letter About Paclitaxel Coated Balloons and Eluting Stents
News | Peripheral Artery Disease (PAD) | January 17, 2019

January 17, 2019 — The U.S. Food and Drug Administration (FDA) issued a letter...

New Appropriate Use Criteria Released for Peripheral Artery Interventions
News | Peripheral Artery Disease (PAD) | December 19, 2018

December 19, 2018 — A new set of appropriate use criteria (AUC) released Dec. 17 by a group of cardiovascular...

Merit Medical Acquires Assets of Vascular Insights LLC
News | Catheters | December 18, 2018

December 18, 2018 — Merit Medical Systems Inc. announced that it has acquired substantially all of the assets of...

Overlay Init